Vaccination of infants with pneumococcal conjugate vaccines in 180, from the health system perspective, would save an estimated $3.2 billion per year worldwide in treatment costs and an additional $2.6 billion in societal costs (from reduced missed work and out-of-pocket expenditures)- for a total of $5.8 billion. These savings would partially offset the estimated global cost of vaccination of $15.5 billion per year.
The cost estimates were calculated in international dollars.
Full Citation:
Chen C, Liceras FC, Flasche S et al.. 2019. Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis. Lancet Global Health. 7(1).
Title of Article: Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis
Author(s): Chen C, Liceras FC, Flasche S et al.
Publication Year: 2019
Publication Name: Lancet Global Health
Publication Volume: 7(1)
Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/30554762/
DOI (Digital Object Identifier): 10.1016/S2214-109X(18)30422-4
Topics: Economics & Return on Investment
Disease Vaccines: Pneumococcal disease/PCV/PPSV
Countries: Global